Serum fatty acid profiling in patients with SDHx mutations: New advances on cellular metabolism in SDH deficiency

Biochimie. 2022 Oct:201:196-203. doi: 10.1016/j.biochi.2022.07.008. Epub 2022 Jul 21.

Abstract

Apart from the oncometabolite succinate, little studies have appeared on extra-mitochondrial pathways in Succinate Dehydrogenase (SDH) genetic deficiency. The role of NADH/NAD+ redox status and dependent pathways was recently emphasized. Therein, fatty acid (FA) metabolism data were collected here in 30 patients with a loss of function (LOF) variant in one SDHx gene (either with a pheochromocytoma/paraganglioma (PPGL) or asymptomatic) and in 22 wild-type SDHx controls (with PPGL or asymptomatic). Blood acylcarnitines in two patients, peroxisomal biomarkers, very long-chain saturated FA (VLCFA), and C20 to C24 n-3 polyunsaturated fatty acids (PUFA), in all patients were measured by mass spectrometry. Preliminary data showed elevated even and odd long- and very long-chain acylcarnitines in two patients with a SDHB variant. In the whole series, no abnormalities were observed in biomarkers of peroxisomal β-oxidation (C27-bile acids, VLCFAs and phytanic/pristanic acids) in SDHx patients. However, an increased hexaene to pentaene PUFA ratio ([TetraHexaenoic Acid + DocosaHexaenoic Acid]/[n-3 DocosaPentaenoic Acid + EicosaPentaenoic Acid]) was noticed in patients with SDHC/SDHD variants vs patients with SDHA/SDHB variants or controls, suggesting a higher degree of unsaturation of PUFAs. Within the group with a SDHx variant, Eicosapentaenoate/Tetracosahexaenoate ratio, as an empiric index of shortening/elongation balance, discriminated patients with PPGL from asymptomatic ones. Present findings argue for stimulated elongation of saturated FAs, changes in shortening/elongation balance and desaturation rates of C20-C24 PUFAs in SDH-deficient patients with PPGL. Overall, oxidation of NADH sustained by these pathways might reflect or impact glycolytic NAD+ recycling and hence tumor proliferation.

MeSH terms

  • Adrenal Gland Neoplasms* / genetics
  • Bile Acids and Salts
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • Electron Transport Complex II / deficiency
  • Fatty Acids / blood*
  • Humans
  • Metabolism, Inborn Errors
  • Mitochondrial Diseases
  • Mutation
  • NAD / metabolism
  • Paraganglioma* / genetics
  • Paraganglioma* / metabolism
  • Paraganglioma* / pathology
  • Pheochromocytoma* / genetics
  • Succinate Dehydrogenase / genetics
  • Succinic Acid / metabolism

Substances

  • Bile Acids and Salts
  • Fatty Acids
  • NAD
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • Succinic Acid
  • Electron Transport Complex II
  • Succinate Dehydrogenase

Supplementary concepts

  • Mitochondrial Complex II Deficiency